Literature DB >> 26847489

CCR4 frameshift mutation identifies a distinct group of adult T cell leukaemia/lymphoma with poor prognosis.

Noriaki Yoshida1, Hiroaki Miyoshi1, Takeharu Kato1,2, Mamiko Sakata-Yanagimoto3, Daisuke Niino1, Hiroaki Taniguchi4, Yukiyoshi Moriuchi4, Masaharu Miyahara5, Daisuke Kurita1, Yuya Sasaki1, Joji Shimono1, Keisuke Kawamoto1, Atae Utsunomiya6, Yoshitaka Imaizumi2, Masao Seto1, Koichi Ohshima1.   

Abstract

Adult T cell leukaemia/lymphoma (ATLL) is an intractable T cell neoplasm caused by human T cell leukaemia virus type 1. Next-generation sequencing-based comprehensive mutation studies have revealed recurrent somatic CCR4 mutations in ATLL, although clinicopathological findings associated with CCR4 mutations remain to be delineated. In the current study, 184 cases of peripheral T cell lymphoma, including 113 cases of ATLL, were subjected to CCR4 mutation analysis. This sequence analysis identified mutations in 27% (30/113) of cases of ATLL and 9% (4/44) of cases of peripheral T cell lymphoma not otherwise specified. Identified mutations included nonsense (NS) and frameshift (FS) mutations. No significant differences in clinicopathological findings were observed between ATLL cases stratified by presence of CCR4 mutation. All ATLL cases with CCR4 mutations exhibited cell-surface CCR4 positivity. Semi-quantitative CCR4 protein analysis of immunohistochemical sections revealed higher CCR4 expression in cases with NS mutations of CCR4 than in cases with wild-type (WT) CCR4. Furthermore, among ATLL cases, FS mutation was significantly associated with a poor prognosis, compared with NS mutation and WT CCR4. These results suggest that CCR4 mutation is an important determinant of the clinical course in ATLL cases, and that NS and FS mutations of CCR4 behave differently with respect to ATLL pathophysiology.
Copyright © 2016 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  CCR4 mutation; adult T cell leukaemia/lymphoma; clinicopathological analyses; prognostic impact; tissue array

Mesh:

Substances:

Year:  2016        PMID: 26847489     DOI: 10.1002/path.4699

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  13 in total

1.  CCR4 is rarely expressed in CCR4-mutated T/NK-cell lymphomas other than adult T-cell leukemia/lymphoma.

Authors:  Yuma Sakamoto; Keiichiro Fujii; Shunji Murase; Satsuki Nakano; Ayako Masaki; Takayuki Murase; Shigeru Kusumoto; Shinsuke Iida; Atae Utsunomiya; Ryuzo Ueda; Takashi Ishida; Hiroshi Inagaki
Journal:  Int J Hematol       Date:  2019-08-29       Impact factor: 2.490

2.  Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma.

Authors:  Keisuke Kataoka; Masako Iwanaga; Jun-Ichirou Yasunaga; Yasunobu Nagata; Akira Kitanaka; Takuro Kameda; Makoto Yoshimitsu; Yuichi Shiraishi; Aiko Sato-Otsubo; Masashi Sanada; Kenichi Chiba; Hiroko Tanaka; Yotaro Ochi; Kosuke Aoki; Hiromichi Suzuki; Yusuke Shiozawa; Tetsuichi Yoshizato; Yusuke Sato; Kenichi Yoshida; Kisato Nosaka; Masakatsu Hishizawa; Hidehiro Itonaga; Yoshitaka Imaizumi; Wataru Munakata; Kotaro Shide; Yoko Kubuki; Tomonori Hidaka; Tsuyoshi Nakamaki; Ken Ishiyama; Shuichi Miyawaki; Ryohei Ishii; Osamu Nureki; Kensei Tobinai; Yasushi Miyazaki; Akifumi Takaori-Kondo; Tatsuhiro Shibata; Satoru Miyano; Kenji Ishitsuka; Atae Utsunomiya; Kazuya Shimoda; Masao Matsuoka; Toshiki Watanabe; Seishi Ogawa
Journal:  Blood       Date:  2017-10-30       Impact factor: 22.113

3.  Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies.

Authors:  Liyanage P Perera; Meili Zhang; Masao Nakagawa; Michael N Petrus; Michiyuki Maeda; Marshall E Kadin; Thomas A Waldmann; Pin-Yu Perera
Journal:  Am J Hematol       Date:  2017-06-05       Impact factor: 10.047

4.  Mogamulizumab for post-transplant relapse of adult T-cell leukemia/lymphoma: a case study.

Authors:  Makoto Hirosawa; Midori Goto; Masahiko Oku; Kenichi Akao; Noriaki Kitamura; Tsukasa Nakanishi; Aya Tanaka; Daisuke Niino; Takehiro Higashi; Hiroaki Morimoto; Junichi Tsukada
Journal:  Int J Hematol       Date:  2022-09-09       Impact factor: 2.319

Review 5.  New developments in the pathology of malignant lymphoma. A review of the literature published from January-April 2016.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2016-06-13       Impact factor: 0.196

6.  Prognostic factors for histiocytic and dendritic cell neoplasms.

Authors:  Joji Shimono; Hiroaki Miyoshi; Fumiko Arakawa; Kensaku Sato; Takuya Furuta; Reiji Muto; Eriko Yanagida; Yuya Sasaki; Daisuke Kurita; Keisuke Kawamoto; Koji Nagafuji; Koichi Ohshima
Journal:  Oncotarget       Date:  2017-10-19

7.  Molecular basis of targeted therapy in T/NK-cell lymphoma/leukemia: A comprehensive genomic and immunohistochemical analysis of a panel of 33 cell lines.

Authors:  Rufino Mondejar; Cristina Pérez; Arantza Onaindia; Nerea Martinez; Julia González-Rincón; Helena Pisonero; Jose Pedro Vaqué; Laura Cereceda; Miguel Santibañez; Margarita Sánchez-Beato; Miguel Angel Piris
Journal:  PLoS One       Date:  2017-05-15       Impact factor: 3.240

Review 8.  Progress in Allogeneic Hematopoietic Cell Transplantation in Adult T-Cell Leukemia-Lymphoma.

Authors:  Atae Utsunomiya
Journal:  Front Microbiol       Date:  2019-10-01       Impact factor: 5.640

Review 9.  Virus-Driven Carcinogenesis.

Authors:  Yuichiro Hatano; Takayasu Ideta; Akihiro Hirata; Kayoko Hatano; Hiroyuki Tomita; Hideshi Okada; Masahito Shimizu; Takuji Tanaka; Akira Hara
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

10.  Mutational Intratumor Heterogeneity is a Complex and Early Event in the Development of Adult T-cell Leukemia/Lymphoma.

Authors:  Amir Farmanbar; Sanaz Firouzi; Wojciech Makałowski; Robert Kneller; Masako Iwanaga; Atae Utsunomiya; Kenta Nakai; Toshiki Watanabe
Journal:  Neoplasia       Date:  2018-07-19       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.